The abundantly tumor‐infiltrating TIGIT+ Tregs showed enhanced suppressive capacity by inhibiting the activation and proliferation of CD8+ T cells in patients with follicular lymphoma. The gene discussed is CD8A; the disease is follicular lymphoma.